These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 10367679

  • 1. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG, Warner WA, Comereski CR, Peden WM, Mezza LE, Damle BD, Siegall CB, Davidson TJ.
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
    Friedman PN, Chace DF, Trail PA, Siegall CB.
    J Immunol; 1993 Apr 01; 150(7):3054-61. PubMed ID: 8454873
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
    Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M.
    Clin Cancer Res; 1997 Mar 01; 3(3):339-45. PubMed ID: 9815690
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
    Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN.
    Clin Cancer Res; 2002 Oct 01; 8(10):3092-9. PubMed ID: 12374676
    [Abstract] [Full Text] [Related]

  • 12. A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies.
    Li J, Sun Y, Zhang J.
    Basic Clin Pharmacol Toxicol; 2006 Dec 01; 99(6):398-404. PubMed ID: 17169119
    [Abstract] [Full Text] [Related]

  • 13. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
    Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP.
    Proc Natl Acad Sci U S A; 1994 Sep 27; 91(20):9514-8. PubMed ID: 7937798
    [Abstract] [Full Text] [Related]

  • 14. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I.
    Int J Cancer; 1994 Jun 15; 57(6):856-64. PubMed ID: 8206679
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I.
    Cancer Res; 1992 Jun 01; 52(11):3189-93. PubMed ID: 1591729
    [Abstract] [Full Text] [Related]

  • 16. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
    Batra JK, Fitzgerald DJ, Chaudhary VK, Pastan I.
    Mol Cell Biol; 1991 Apr 01; 11(4):2200-5. PubMed ID: 2005905
    [Abstract] [Full Text] [Related]

  • 17. Characterization of single-chain antibody (sFv)-toxin fusion proteins produced in vitro in rabbit reticulocyte lysate.
    Nicholls PJ, Johnson VG, Andrew SM, Hoogenboom HR, Raus JC, Youle RJ.
    J Biol Chem; 1993 Mar 05; 268(7):5302-8. PubMed ID: 8444903
    [Abstract] [Full Text] [Related]

  • 18. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
    Kuan CT, Pastan I.
    Proc Natl Acad Sci U S A; 1996 Feb 06; 93(3):974-8. PubMed ID: 8577771
    [Abstract] [Full Text] [Related]

  • 19. Immunological hormone atrophy by gonadotropin-based drug.
    Li J, Zhang J.
    Int J Exp Pathol; 2006 Dec 06; 87(6):495-9. PubMed ID: 17222217
    [Abstract] [Full Text] [Related]

  • 20. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
    Siegall CB.
    Recent Results Cancer Res; 1996 Dec 06; 140():51-60. PubMed ID: 8787077
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.